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Abstract
Purpose: To evaluate cardiovascular and psychiatric morbidity in patient visits with obstructive sleep apnea (OSA) with
insomnia (OSA+Insomnia) versus OSA without insomnia (OSA-Insomnia) in a nationally representative US sample.
Methods: A retrospective case-control study of epidemiologic databases (National Ambulatory Medical Care Survey and
National Hospital Ambulatory Medical Care Survey) representing an estimated 6 standard error (SE) 62,253,91065,274,747
(unweighted count = 7234) patient visits with diagnosis of OSA from 1995–2010, was conducted. An estimated
3,994,1046791,386 (unweighted count = 658) were classified as OSA+Insomnia and an estimated 58,259,80664,849,800
(unweighted count = 6576) as OSA-Insomnia. Logistic regression analysis was carried out using OSA+Insomnia versus OSAInsomnia as the dependent variable, and age (.50 years versus #50 years), sex, race (‘White’ versus ‘non-White’), essential
hypertension, heart failure, ischemic heart disease, cardiac dysrhythmia, cerebrovascular disease, diabetes, obesity,
hyperlipidemia, depressive, anxiety, and adjustment disorders (includes PTSD), hypersomnia and all medications used as
independent variables. All comorbidities were physician diagnosed using the ICD9-CM.
Results: Among patient visits with OSA, an estimated 6.4%60.9% also had insomnia. Logistic regression analysis revealed
that the OSA+Insomnia group was significantly more likely to have essential hypertension (all ICD9-CM codes 401)
(OR = 1.83, 95% CI 1.27–2.65) and provisionally more likely to have cerebrovascular disease (ICD9-CM codes 430–438)
(OR = 6.58, 95% CI 1.66–26.08). The significant OR for cerebrovascular disease was considered provisional because the
unweighted count was ,30.
Conclusions: In a nationally representative sample, OSA+Insomnia was associated significantly more frequently with
essential hypertension than OSA-Insomnia, a finding that has not been previously reported. In contrast to studies that have
considered patient self-reports of psychological morbidity, the absence of a significant association with psychiatric disorders
in our study may be indicative of the fact that we considered only physician-rated psychiatric syndromes meeting ICD9-CM
criteria. Our findings among the OSA+Insomnia group are therefore most likely conservative.
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mechanisms underlying the pathogenesis of both the cardiovascular and psychiatric disorders that are encountered in OSA and
insomnia.
OSA is characterized by intermittent hypoxia, which can lead to
oxidative stress, systemic inflammation, vascular endothelial
dysfunction, and an increase in sympathetic nervous system
(SNS) activity, putting OSA patients at risk for cardiovascular
disorders [6,12]. The allostatic challenge induced by the arousals

Introduction
Obstructive sleep apnea (OSA) [1] and insomnia [2,3] are two
of the most commonly encountered sleep disorders. It is well
recognized that both OSA [4–6] and insomnia [7,8] are
independently associated with cardiovascular disease; and OSA
[9,10] and insomnia [10,11] are also independently associated
with psychiatric disorders. Activation of the hypothalamicpituitary-adrenal (HPA) axis is believed to be one of the major
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of OSA is also thought to activate the HPA axis [13,14]. This
elevated SNS and HPA axis activity can lead to an upregulation of
the renin-angiotensin-aldosterone system, potentially leading to
the development of hypertension [13,15]. Elevated SNS and HPA
activity can also lead to an increase in cortisol levels, which have
been implicated in psychiatric disorders such as depression
[16,17]. Various studies have also associated insomnia with
activation of the HPA axis and SNS [18–21]. Corticotropin
releasing factor hyperactivity, due to early-life stress or genetic
predisposition, can lead to an amplification of the stress response,
followed by prolonged and exaggerated sleep difficulties following
stress and the subsequent development of chronic insomnia
[20,22]. This chronic hyperarousal puts insomnia patients at risk
for cardiovascular disease [23] and mood disorders [20] also
associated with HPA axis hyperactivity. Insomnia may be a
consequence of the enhanced HPA axis activity seen in OSA
[13,14,18]. Alternatively, insomnia may cause or exacerbate OSA
by creating repeated sleep fragmentation, which can cause
disruptions of the upper airway muscle tone, leading to greater
airway collapsibility and the development of OSA [18,24,25]. The
shared physiological mechanism of HPA hyperactivity underlying
both OSA and insomnia may explain the high comorbidity of
these two sleep disorders.
The comorbidity of OSA and insomnia, also referred to as
‘Sleep apnea plus’ [26], was reported over 4 decades ago [27] and
various studies [26,28–42] have examined the prevalence of
insomnia in sleep apnea reporting prevalence rates ranging from
7.3% [34] to 57.6% [28]. To our knowledge, there are 3 reported
studies [28,34,36] that have directly [36] or indirectly [28,34]
examined the frequency of both cardiovascular and psychiatric
comorbidities in OSA with insomnia in epidemiologically representative samples. There are differences in the definition of the
primary mediating variable of insomnia in each of the studies
[34,36]. A study of data from the 2005–2008 United States
National Health and Nutrition Examination Survey (NHANES)
[36] which largely uses patient-reports of health professional
diagnosed disorders, reports a 43% frequency of insomnia in OSA
(n = 546) versus 30% frequency of insomnia in individuals without
OSA (n = 12,047). In this study [36] the participants were asked
questions regarding the frequency of difficulty falling asleep, of
prolonged nocturnal awakenings, and of undesired early morning
awakening over the past month. Individuals who described
experiencing at least one of any of the above insomnia symptoms
‘often’ (defined as 5–15 times per month) or ‘almost always’
(defined as 16–30 times per month) were classified as having
insomnia. Results from the Icelandic Sleep Apnea Cohort Study
[28] indicate a 57.6% frequency of insomnia in polysomnographically diagnosed obstructive sleep apnea (n = 824) versus 31%
among controls from the general population (n = 762) in Iceland.
Insomnia was defined [28] using answers to 2 questions from the
Basic Nordic Sleep Questionnaire which described the patients’
experience over the past month: ‘I have difficulties falling asleep at
night’ and ‘I wake up often during the night’. The patients rated
their response on a 5-point scale where a rating of ‘i’ denoted
‘never/almost never’, a rating of ‘ii’ denoted ‘less than once a
week’, a rating of ‘iii’ denoted ‘once or twice a week’, a rating of
‘iv’ denoted ‘three to five times a week’, a rating of ‘v’ denoted
‘every day or almost every day of the week’. Those with scores $4
were defined as having insomnia. Finally, data from the
prospective Norwegian Hordaland Health Study (n = 6892) found
a much lower frequency of comorbid insomnia in sleep apnea of
7.3% versus a 4.9% frequency of insomnia without sleep apnea
[34]. In this study [34], more stringent diagnostic criteria were
used including an assessment of the effect of insomnia on
PLOS ONE | www.plosone.org

functioning and longer duration of symptoms, and this may
explain the lower frequency of comorbid sleep apnea and
insomnia in this sample. Insomnia symptoms were assessed [34]
using the Karolinska Sleep Questionnaire where insomnia
diagnosis was based upon 4 items each rated along a 5-point
scale with ratings denoting ‘never’, ‘rarely (a few times per year)’,
‘sometimes (a few times per month)’, ‘mostly (several times a
week)’, or ‘always’. Subjects were categorized as having insomnia if
they reported sleep onset insomnia, sleep maintenance insomnia,
early morning wakening or a combination, ‘several times a week’
or ‘always’ during the past 3 months, in addition to reporting
impaired work performance during the preceding year caused by
sleep problems.
The role of comorbid insomnia on OSA severity remains
inconclusive as insomnia complaints in OSA have been associated
with more severe OSA [35,43], milder OSA [31] and no
significant objective differences in sleep parameters [26,28,37,44]
in various studies. The co-occurrence of OSA and insomnia has
other potentially important clinical implications as it could have an
additive effect on the comorbidities that have been independently
associated with both of these conditions. Studies that have
examined comorbidities in OSA with insomnia generally report
a higher frequency of emotional and psychiatric symptoms
[26,28,31,34–36,44,45], but not cardiovascular symptoms including patient-reported physician diagnosed hypertension [28] and
patient-reported health-professional diagnosed hypertension, myocardial infarction, congestive heart failure and stroke [36]. One
exception to these findings is the recent report by Sivertsen et al.
[34] that found a significantly higher frequency of patient-reported
stroke, but not angina or myocardial infarction, in the OSA with
insomnia group versus OSA alone. This divergent finding may be
due to the more stringent criteria for the diagnosis of insomnia
used in this study [34].
As a follow-up to recent epidemiologic studies that have directly
[36] or indirectly [28,34] addressed both cardiovascular and
psychological/psychiatric morbidity in OSA plus insomnia, we
carried out a more expanded analysis of several major cardiovascular and psychiatric disorders that have been previously
associated with OSA alone, in our OSA plus insomnia sample.
In this study we examined the frequency of physician diagnosed
cardiovascular and psychiatric disorders that are commonly
associated with OSA alone, among patient visits with OSA plus
insomnia, in a randomly selected, nationally representative sample
of patient visits in the US, to doctors’ offices, and hospital
outpatient and emergency departments for all possible diagnoses.
In order to examine the possible effect of insomnia on OSA related
comorbidities, we used patient visits with OSA without comorbid
insomnia as the reference group in our analyses. The objective of
this study was to evaluate the possible additive effect of comorbid
insomnia in OSA on cardiovascular and psychiatric disorders that
are commonly known to be associated with OSA alone, in a large
nationally representative sample of patient visits for OSA, after
controlling for potential confounding factors such as sex, age, race,
obesity, diabetes, hyperlipidemia, all medications and hypersomnia.

Methods
Using a retrospective cross-sectional design, we examined data
collected from 1995 to 2010 by the National Ambulatory Medical
Care Survey (NAMCS) and National Hospital Ambulatory
Medical Care Survey (NHAMCS) [46]. The NAMCS and
NHAMCS are publicly accessible databases available at http://
www.cdc.gov/nchs/ahcd.htm. The University of Western Ontario
2
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7. Psychiatric Disorders: The following psychiatric disorders were
coded largely based upon the literature on psychiatric
comorbidities in OSA: (i) Depressive disorders: coded for all
patient visits with all (including 5th digits) ICD9-CM codes
296.2 denoting ‘Major Depressive Disorder, Single Episode’,
all ICD9-CM codes 296.3 denoting ‘Major Depressive
Disorder, Recurrent Episode’, ICD9-CM code 296.82 denoting ‘Atypical Depressive Disorder’, and ICD9-CM code 311
denoting ‘Depressive Disorder, Not Elsewhere Classified’; (ii)
Anxiety disorders: coded for all patient visits with all (including 5th
digits) ICD9-CM codes 300.0 denoting ‘Anxiety states’,
‘Anxiety state, unspecified’, ‘Panic disorder without agoraphobia’, ‘Generalized anxiety disorder’, and ‘Other anxiety states’.
(iii) Adjustment Disorders: coded for patient visits with all
(including 5th digits) ICD9-CM codes 309 denoting ‘Adjustment reaction’, ‘Adjustment disorder with depressed mood’,
‘Prolonged depressive reaction’, ‘Adjustment reaction with
predominant disturbance of other emotions’, ‘Adjustment
disorder with disturbance of conduct’, ‘Adjustment disorder
with mixed disturbance of emotions and conduct’, ‘Other
specified adjustment reactions’ including ‘Posttraumatic stress
disorder’, and ‘Unspecified adjustment reaction’.
8. Confounding factors: The following conditions that are commonly
encountered in both cardiovascular and psychiatric disorders
were controlled for statistically: (i) Hyperlipidemia: included any
patient visit where at least one of the 3 possible diagnoses were
coded using ICD9-CM codes 272.0 to 272.4, which denote
hypercholesterolemia, hyperglyceridemia, hyperlipidemia, and
hyperchylomicronemia; (ii) Obesity: included any patient visit
where at least one of the 3 possible diagnoses were coded using
the ICD9-CM codes 278, 278.0, 278.00, 278.01 related to
obesity and morbid obesity; (iii) Diabetes Mellitus: included any
patient visit where at least one of the 3 possible diagnoses were
coded using ICD9-CM codes 250, which code for both noninsulin dependent and insulin- dependent diabetes mellitus and
their complications; (iv) Medications: denoted patient visits
associated with use of 1 to 8 medications (in NAMCS/
NHAMCS from 1995–2002, one to six medications per visit
were coded, from 2003 to 2010 one to eight medications per
visit were coded) versus patient visits with no medications. This
variable was created as a wide range of medications can
theoretically confound the association between sleep apnea and
insomnia. A separate variable ‘Z drugs’ was also created to just
denote zaleplon, zolpidem, and eszopiclone. The ‘Z drugs’
variable was created to test whether hypnotic medication use in
our sample of OSA+Insomnia patients was consistent with earlier
reports [26,33] of increased hypnotic use in OSA+Insomnia
patients, however the more general ‘Medications’ variable was
used to control statistically for the possible confounding effect
of any medications that the patients might have been using. A
‘Tobacco smoking’ variable was also created to denote patient
visits associated with tobacco smoking versus all other visits
(including visits coded as non-smokers, non-responders or
‘blank’ or unknown in the various studies). There was some
lack of consistency in the way the patient visits not associated
with tobacco smoking were coded in the databases from 1995
to 2010.
9. Demographic factors: (i) Age was categorized as .50 years versus
#50 years; (ii) Race was categorized as a dichotomous variable
denoting ‘White’ and ‘Non-White’ (which included ‘Black’,
‘Asian’, ‘Native Hawaiian’, ‘Pacific Islander’, ‘American
Indian’, ‘Alaska Native’, and ‘More than one race reported’).
Age, race and sex were controlled for in our statistical analyses.

Office of Research Ethics determined that ethics approval was not
required for research involving publicly accessible information
such as the NAMCS/NHAMCS databases. The NAMCS and
NHAMCS are national surveys conducted by the National Center
for Health Statistics (NCHS) at the Centers for Disease Control
and Prevention (CDC), and use a multi-stage probability design to
collect nationally representative samples of health care visits to
physicians’ offices (NAMCS) and hospital outpatient departments
and emergency rooms (NHAMCS) in the US. Full details of the
multi-stage data collection method are available on the NAMCS/
NHAMCS website [46]. The NAMCS and NHAMCS Public Use
Data files from 1995 to 2010 were merged into one database for
our analyses. The NAMCS and NHAMCS represent patient visits
for all possible diagnostic groups, and document up to 3 ‘reasons
for visit’ and 3 diagnoses per patient visit which are diagnosed and
coded by a physician using the International Classification of
Diseases, 9th edition, Clinical Modification (ICD9-CM) [47]. In
order to preserve the confidentiality of participating patients and
physicians, all survey data in the databases are masked through the
inclusion of variables for stratification, sampling unit, and patient
visits [46]. NCHS standards for reliability state that estimates
based on fewer than 30 cases are considered unreliable [48].

Variables studied
The following variables were created for our analyses.
1. Sleep Apnea: included any patient visit where one of the 3
possible diagnoses were coded using ICD9-CM code 327.23
denoting ‘Obstructive Sleep Apnea’ (first introduced in 2006),
code 780.57 denoting ‘Other and Unspecified Sleep Apnea’,
and code 780.53 denoting ‘Hypersomnia with Sleep Apnea’, or
any patient visit where one of the 3 ‘reasons for visit’ was coded
as ‘Sleep Apnea’.
2. Insomnia: included any patient visit where at least one of the 3
possible diagnoses was coded using ICD9-CM code 307.41
denoting ‘Transient Disorder of Initiating or Maintaining
Sleep’, code 307.42 denoting ‘Persistent Disorder of Initiating
or Maintaining Sleep’, code 780.51 denoting ‘Insomnia with
Sleep Apnea’ or code 780.52 denoting ‘Other Insomnia’, or
any patient visit where one of the 3 ‘reasons for visit’ was coded
as ‘Insomnia’.
3. Sleep Apnea plus Insomnia (OSA+Insomnia): denoted patient visits
with both sleep apnea and insomnia derived using the codes for
the ‘Sleep Apnea’ and ‘Insomnia’ variables above.
4. Sleep Apnea without Insomnia (OSA-Insomnia): denoted patient visits
with sleep apnea without insomnia, where both variables were
derived using the codes for the ‘Sleep Apnea’ and ‘Insomnia’
variables above.
5. Sleep Apnea Plus: A dichotomous variable denoting OSA+Insomnia
versus OSA-Insomnia, derived using the ‘Sleep Apnea’ and
‘Insomnia’ variables above.
6. Cardiovascular Disorders: The following cardiovascular disorders
were coded largely based upon the literature on the
cardiovascular comorbidities in OSA: (i) Essential hypertension:
coded for patient visits with all ICD9-CM codes 401 (401,
401.0 to 401.9); (ii) Heart failure: coded for patient visits with all
ICD9-CM codes 428 (428, 428.0 to 428.9) (iii) Ischemic heart
disease: coded for patient visits with all ICD9-CM codes 410–
414; (iv) Cardiac dysrhythmias: coded for patient visits with all
ICD9-CM codes 427 (427, 427.0 to 427.9); and (v) Cerebrovascular disease: coded for all patient visits with ICD9-CM codes
430–438.
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cerebrovascular disease finding is provisional as the unweighted
count was ,30. There were no significant differences (Table 2) in
the frequencies of the other cardiovascular diagnostic groups
including ‘Heart failure’, ‘Cardiac dysrhythmia’, and ‘Ischemic heart
disease’, or psychiatric disorders including ‘Depressive disorders’,
‘Anxiety disorders’, or ‘Adjustment Disorders’. However, it should be
noted that these groups all had unweighted counts of ,30.
Similarly, sex, race, and potential confounders including ‘Diabetes’,
‘Hyperlipidemia’, ‘Medication use’ and ‘Hypersomnia’ did not differ
between the OSA+Insomnia versus OSA-Insomnia groups.

10. Hypersomnia: included any patient visit where at least one of
the 3 possible diagnoses were coded using ICD9-CM code
780.54 denoting ‘Other hypersomnia’, or any patient visit
where one of the 3 ‘reasons for visit’ was coded as
‘Hypersomnia’. We controlled for hypersomnia as it can
confound the type of insomnia the patient is experiencing.
Our study sample did not delineate the type of insomnia eg.,
sleep onset, sleep maintenance or early morning wakening,
and sleep maintenance insomnia in OSA has been
associated with hypersomnia [28]. Secondly, insomnia and
hypersomnia can coexist in many cases of OSA [31], and
the presence of hypersomnia in the OSA+Insomnia patient
could be a confounding factor for other comorbidities.

Discussion
We examined the frequency and comorbidity of OSA+Insomnia
with cardiovascular and psychiatric disorders that are commonly
associated with obstructive sleep apnea alone, in a nationally
representative sample of an estimated (6SE) 62,253,91065,
274,747 (unweighted count = 7234) patient visits for obstructive
sleep apnea in the US, from 1995 to 2010. To our knowledge, our
study represents the largest sample of patients with OSA+Insomnia
that have been examined to date [36]. In order to examine the
possible effect of insomnia on OSA related comorbidities, we used
patient visits with OSA without comorbid insomnia (OSA-Insomnia)
as the reference group in our analyses. The estimated (6SE)
frequency of insomnia in our obstructive sleep apnea sample was
6.4%6SE (60.9%), which is lower than the 21.9% to 57.6%
prevalence of insomnia in sleep apnea reported in many previous
studies [26,28–33,35,36] and comparable to the 7.3% prevalence
of insomnia in obstructive sleep apnea reported in a recent
epidemiologic study [34], which used more stringent criteria to
diagnose insomnia. The wide range of reported frequencies most
likely are a reflection of the wide range of criteria used to diagnose
insomnia, most of which do not use the effect of insomnia on
daytime functioning in their diagnostic criteria. In our study,
insomnia was diagnosed if one of the 3 possible diagnoses for the
patient visit was coded by the physician using the ICD9-CM codes
(307.41, 307.42, 780.51, 780.52) for insomnia or if one of the 3
possible ‘reasons for visit’ for the patient was coded by the
physician as ‘insomnia’, suggesting that the symptom of insomnia
would have to be significant and likely severe for a patient to
report insomnia as one of their chief complaints during a visit to
their doctor’s office or hospital, and our results therefore are likely
to be conservative. The relatively lower frequency of OSA+Insomnia
in our sample of OSA patient visits therefore most likely also is a
reflection of the more conservative criteria used to diagnose
insomnia in our study, and consistent with other studies [34] that
have employed more stringent criteria to diagnose insomnia.
As for other possible confounding factors, the frequency of
‘Obesity’ was significantly lower (OR = 0.08, 95% CI 0.03–0.22) in
the OSA+Insomnia group, which is similar to the findings of one
study [36]; other studies have found no difference [28] and higher
body mass index [34] in the OSA+Insomnia group. ‘Diabetes’ and
‘Hyperlipidemia’ were not significantly different between OSA+Insomnia versus OSA-Insomnia, which is consistent with previous
studies that have examined diabetes [28,34,36] and total
cholesterol [36] in OSA+Insomnia. ‘Hypersomnia’ was not significantly
different between our OSA+Insomnia group versus OSA-Insomnia.
This is in contrast to the report that OSA patients with a disorder
of maintaining sleep were sleepier, as measured by the Epworth
Sleepiness Scale, than OSA patients without a disorder of
maintaining sleep [28]. Since we did not have information about
whether patients had a disorder of initiating or maintaining sleep,
our non-significant findings most likely represent the possible
heterogeneity of the insomnia diagnosis in our sample. As

Statistical analysis
All analyses were conducted using the Complex Samples
module of SPSS version 20 [49] in order to account for the
multistage probability sampling design used by the NAMCS and
NHAMCS. The relation of the Sleep Apnea Plus variable (ie.,
OSA+Insomnia versus OSA-Insomnia) to the cardiovascular and
psychiatric disorders was examined using logistic regression
analysis using Sleep Apnea Plus as the dependent variable, after
controlling for potential confounders such as age (.50 years versus
#50 years), sex (male vs female), race (‘White’ versus ‘non-White’),
‘Diabetes mellitus’, ‘Obesity’, ‘Hyperlipidemia’, ‘Hypersomnia’ and ‘Medications’ use. The smoking variable was not used in the logistic
regression model as there was no significant difference in the
frequency of smoking among the OSA+Insomnia versus OSAInsomnia groups. Odds ratios (OR) were calculated to determine
whether the frequencies of the independent variables were
significantly different between the OSA+Insomnia versus OSAInsomnia groups.

Results
The frequency of OSA+Insomnia in our sample of sleep apnea
patient visits (total unweighted count = 7234) was 6.4%6SE
(60.9%) (6.1%60.9% male and 6.9%61.2% female) (unweighted
count = 658). Table 1 summarizes the demographic characteristics
of the sample. Compared to OSA-Insomnia, patients with
OSA+Insomnia were older (p,0.05) and more likely (p,0.001) to
be prescribed hypnotics such as the ‘Z drugs’ (zolpidem,
eszopiclone, zaleplon). Table 2 summarizes the results of the
logistic regression analysis using ‘Sleep Apnea Plus’ (OSA+Insomnia vs
OSA-Insomnia) as the dependent variable. The logistic regression
model indicates that the frequency of patients over age 50 years is
no longer significantly higher (Odds ratio or OR = 1.23, 95% CI
0.87–1.74) in the OSA+Insomnia group versus the OSA-Insomnia
group, after controlling for comorbidities, other demographic and
potential confounding factors. In contrast to the OSA-Insomnia
group, there was a lower frequency of ‘Obesity’ (OR = 0.08, 95%
CI 0.03–0.22) in the OSA+Insomnia group. As for comorbidities, in
contrast to the OSA-Insomnia group, the OSA+Insomnia group had a
significantly higher frequency of ‘Essential hypertension’ (OR = 1.83,
95% CI 1.27–2.65) and ‘Cerebrovascular disease’ (OR = 6.58, 95% CI
1.66–26.08). Among the OSA+Insomnia group, an estimated 14.5%
(61.3%) had ‘Essential hypertension’ (total unweighted count in OSA
sample = 523; unweighted count = 35 in OSA+Insomnia group) in
contrast to 9.4% (60.6%) in the OSA-Insomnia group. Similarly,
among the OSA+Insomnia group, an estimated 1.6% (60.9%) had a
diagnosis of ‘Cerebrovascular disease’ (total unweighted count in OSA
sample = 24, unweighted count = 4 in OSA+Insomnia group) in
contrast to 0.4% (60.2%) in the OSA-Insomnia group. The
PLOS ONE | www.plosone.org
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Table 1. Demographic and clinical features of the obstructive sleep apnea (OSA) sample.

Demographic or Clinical Feature

All OSA visits

OSA+Insomnia

OSA-Insomnia

Estimated (6SE) number of visits (unweighted
count)

62,253,91065,274,747 (7234)

3,994,1046791,386 (658)

58,259,80664,849,800 (6576)

Age* (6SE) years

50.8060.59

53.3561.13

50.6260.61

Sex (6SE) % female (F) vs male(M)

39.5%61.3% F, 60.5%61.3% M

42.6%63.9% F, 57.4%63.9% M

60.7%61.3%F, 39.3%61.3%M

Race (6SE) %: ‘White’(W) vs%‘Black/African
American (B)’ vs %‘Other’a

86.1%60.9% W, 10.1%60.8% B,
3.8%60.5% ‘Other’

85.6%63.7% W, 11.4%63.1% B,
3.1%62.2% ‘Other’

86.1%60.9% W, 10.1%60.8% B,
3.8%60.4% ‘Other’

12.4%61.9%

3.1%60.6%

8.3%62.0 S, 91.7%62.0 O

11.3%60.8 S, 88.7%60.8 O

‘Z drugs’* (zolpidem, eszopiclone, zaleplon) use 3.7%60.6%
%(6SE)
Tobacco Smoking% (6SE): ‘Smokers’ (S) vs All
other visits ‘Other’ (O)b

11.1%60.8% S, 88.9%60.8% O

* Significantly (p,0.05) different between the OSA+Insomnia vs. OSA-Insomnia groups.
a
‘Other’ denotes: Asian/Native Hawaiian/Pacific Islander/American Indian/Alaska Native/More than one race reported.
b
‘Other’ responses denotes: non-smoker, blank, and unknown.
doi:10.1371/journal.pone.0090021.t001

while findings related to ‘Cerebrovascular disease’ (unweighted cases in
OSA+Insomnia = 4) should be considered provisional, because of the
smaller number of unweighted cases. Previous studies have not
found a higher frequency of hypertension [28,34,36] in OSA+Insomnia, where patients were categorized as having hypertension
using the following criteria: if they had indicated that they had
been diagnosed by a doctor and were on antihypertensive
medication [28]; if they self-reported health-professional diagnosed hypertension at any point and had 3 consecutive blood
pressure measurements where systolic blood pressure was
.140 mm Hg and diastolic blood pressure was .90 mm Hg
[36]; or had higher systolic blood pressure at baseline [34]. As for
cerebrovascular disease, one study [34] reported a higher
frequency of strokes in OSA+Insomnia and the patient was coded
as having a stroke based upon a positive response to the question
whether they have had a stroke, and the diagnostic criteria for
insomnia were the most stringent. While another study [36], which

expected, the OSA+Insomnia group was more likely to be using
hypnotic medications (Table 1); however, overall, there was no
significant difference in the frequency of overall medication use
(Table 2) between OSA+Insomnia and OSA-Insomnia.
There was a significantly higher frequency of ‘Essential
hypertension’ (OR = 1.83, 95% CI 1.27–2.65) and ‘Cerebrovascular
disease’ (OR = 6.58, 95% CI 1.66–26.08) in the OSA+Insomnia
versus the OSA-Insomnia group, suggesting an additive effect of
insomnia on these disorders. This has not been previously
reported. Essential hypertension and cerebrovascular disease were
both physician diagnosed at the time of the study and coded using
the ICD9-CM [47], and this finding among a randomly selected
epidemiologically representative sample of patient visits most likely
represents a clinically significant finding. The NCHS standards for
reliability require that estimates be based on at least 30 sample
records [48]; our findings related to ‘Essential hypertension’
(unweighted cases in OSA+Insomnia = 35) are therefore definitive,

Table 2. Results of logistic regression analysis using Sleep Apnea Plus as the dependent variable.

Independent Variable

Wald Statistic (Wald F)

Significance level
(Bonferroni Correction)

Odds ratio (95% CI) (OSA+Insomnia vs
OSA-Insomnia)*

‘Essential hypertension’

10.400

0.001

1.83 (1.27–2.65)

‘Cerebrovascular disease’

7.209

0.007

6.58 (1.66–26.08)

‘Heart failure’

0.937

0.333

0.42 (0.07–2.46)

‘Cardiac dysrhythmia’

0.007

0.934

0.93 (0.15–5.90)

‘Ischemic heart disease’

0.896

0.344

0.39 (0.05–2.77)

‘Depressive disorders’

0.129

0.720

0.81 (0.26–2.51)

‘Anxiety disorders’

0.000

0.988

1.01 (0.27–3.75)

‘Adjustment Disorders’

0.704

0.402

0.40 (0.05–3.38)

Sex (male vs. female)

0.408

0.523

0.89 (0.62–1.28)

Race (White vs. Non-White)

0.090

0.764

0.91 (0.47–1.74)

‘Obesity’

25.434

0.000

0.08 (0.03–0.22)

‘Diabetes’

0.887

0.347

0.55 (0.16–1.90)

‘Hyperlipidemia’

0.010

0.921

1.07 (0.25–4.68)

‘Medications’ (any medication vs no medication)

3.833

0.051

0.63 (0.39–1.00)

‘Hypersomnia’

0.888

0.346

1.47 (0.66–3.29)

2

*Corrected model using all variables significant at p,.001, with pseudo R (Nagelkerke’s) = 0.046.
doi:10.1371/journal.pone.0090021.t002
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used less stringent diagnostic criteria for insomnia, and in which a
patient was coded as having a stroke based upon self-reported
health-professional diagnosis of stroke at any time, did not find a
positive association between stroke and OSA+Insomnia. Similar to
our study, previous studies [34,36] did not find a significantly
(p,0.05) higher frequency of angina or myocardial infarction [34]
and myocardial infarction or congestive heart failure [36] in their
OSA+Insomnia sample. We also examined the frequency of ICD9CM coded cardiac dysrhythmias, as arrythmias such as atrial
fibrillation have been associated with OSA, and may be a feature
of ANS activation, however we found no significant differences in
their frequency in the OSA+Insomnia sample in comparison to the
OSA-Insomnia sample.
In contrast to the results of previous studies [26,31,34–36,44]
that have compared OSA+Insomnia patients to those with OSAInsomnia, we did not find a higher frequency of ‘Depressive disorders’
or ‘Anxiety disorders’ diagnosed using ICD9-CM criteria. One
potential reason for this is the method used for assessing
psychiatric/mental health symptoms. Previous studies have
assessed psychiatric disorder status using established self-report
scales [34,35,44], questionnaires designed to enquire about mood
[36], mental symptoms, and previous psychiatric diagnoses
[26,31]. Those scoring high on these psychiatric scales and selfreport questionnaires that usually screen for psychiatric disorders,
may not have actually met all the diagnostic criteria for a
psychiatric disorder. While previous studies that have employed
patient-self reports of psychiatric comorbidity have shown that
patients with OSA+Insomnia may be more likely to feel anxious or
depressed [26,34–36,44], our findings indicate that those with
OSA+Insomnia are not more likely to actually be diagnosed with a
depressive or anxiety disorder than patients with OSA-Insomnia,
diagnosed using ICD9-CM diagnostic criteria. Some studies have
not noted higher frequency of psychiatric comorbidity in OSA
patients with insomnia. For example, one study has reported that
insomnia in patients with OSA had negative effects on depression
and anxiety, but only in men, and not women [37]. Another recent
study found no significant difference between those with OSA and
insomnia and those with OSA alone on the Beck Depression
Inventory or the State-Trait Anxiety Inventory [50]. However,
they did find that those with OSA and insomnia were more likely
to report having received a psychiatric diagnosis [50]. These
findings suggest that there is some variability in the reports of a
higher frequency of psychiatric morbidity in OSA patients with
insomnia. Our sample was selected from a nationally representative sample for all possible diagnoses, and the unweighted counts
of patient visits with both OSA+Insomnia and a psychiatric
diagnosis was ,30, making the estimate not as reliable [48], and
increasing the risk of a Type II error.
Some of the limitations of this study are the fact that our results
are based upon retrospective cross-sectional data and therefore it is
not possible to arrive at any conclusions regarding causation. The
retrospective design prevented the independent evaluation of the
patients studied and checking of the diagnostic criteria used. The
basic sampling unit in the NAMCS and NHAMCS is the patient
visit, and it is possible that some of the data points represent the
same patient seen for more than 1 visit during the data collection
period. We do not have polysomnographic data to confirm the
physician diagnoses of obstructive sleep apnea. While such
confirmation would be ideal, it is rare for large epidemiological
studies to collect such information [34,36]. In fact, only one

epidemiological study examining comorbidities in OSA+Insomnia
used polysomnography to make an OSA diagnosis [28]. Other
epidemiological studies have used less stringent criteria than the
present study to diagnose OSA including self-report of physician
diagnosis [36] and two self-report questions on snoring and
breathing cessation during sleep [34]. As such, our results
represent relatively stringent diagnostic criteria for OSA.
Another potential confounder in our database is the fact that the
ICD9- CM diagnostic codes used to denote sleep apnea (ICD9CM codes 780.53 denoting ‘Hypersomnia with Sleep Apnea’ and
780.57 denoting ‘Other and Unspecified Sleep Apnea’) did not
specifically mention obstructive sleep apnea, until the ICD9-CM
code 327.23 denoting ‘Obstructive Sleep Apnea’ was first
introduced in 2006. However, the earlier codes alone have been
used to diagnose obstructive sleep apnea in other reports from our
database [51]. We also diagnosed obstructive sleep apnea when
one of the 3 possible ‘reasons for visit’ was coded as ‘sleep apnea’.
We excluded patient visits coded as Cheyne-Stokes respiration and
central sleep apnea (added to ICD9-CM from 2006 onwards) from
our OSA variable, and therefore it is unlikely that we have
inadvertently included central sleep apnea cases. The above
factors could have led to the misclassification of some patient visits
as obstructive sleep apnea, however this is mitigated by the fact
that the comparison group also consisted of patients with sleep
apnea (without insomnia), which would potentially cancel out
some of the error introduced by the diagnostic codes used to code
for obstructive sleep apnea. Finally, the unweighted number of
cases of cerebrovascular disease which is significantly more
frequent in OSA+Insomnia is ,30 and therefore the estimate does
not meet the criteria for reliability [48] and the findings related to
cerebrovascular disease provide directions for future studies and
can only be considered to be provisional.

Conclusions
Our findings that hypertension and possibly cerebrovascular
disease are more common in those with OSA+Insomnia are
consistent with theories suggesting that a possible linking
mechanism between insomnia and OSA is the hyperactivity of
the HPA axis [14,18,30] and the sympathetic nervous system [18].
OSA leads to HPA hyperactivity, which then leads to hyperarousal
and insomnia, which perpetuates these enhanced cortisol levels,
and eventually leads to the development of other diseases
associated with HPA hyperactivity like cardiovascular disease
[13,14]. If this theory is correct, then once the OSA has been
addressed, one would expect to also see improvements in
insomnia, and cardiovascular symptoms. Studies have shown that
once OSA is addressed with continuous positive airway pressure
(CPAP), surgical intervention, or nasal dilator strip therapy,
insomnia symptoms [52–55] and symptoms of hypertension [56]
improve dramatically. Having insomnia actually also predicts
poorer CPAP adherence [40,57]. These findings stress the
important association between insomnia and sleep apnea, and
highlight the necessity of correct diagnosis of comorbid OSA+Insomnia.
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